Apogee Therapeutics Statistics
Share Statistics
Apogee Therapeutics has 58.51M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 58.51M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 16.03K |
| FTD / Avg. Volume | 3.41% |
Short Selling Information
The latest short interest is 6.81M, so 11.64% of the outstanding shares have been sold short.
| Short Interest | 6.81M |
| Short % of Shares Out | 11.64% |
| Short % of Float | 14.44% |
| Short Ratio (days to cover) | 20.47 |
Valuation Ratios
The PE ratio is -8.32 and the forward PE ratio is -15.09.
| PE Ratio | -8.32 |
| Forward PE | -15.09 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 1.84 |
| P/FCF Ratio | -9.32 |
| PEG Ratio | n/a |
Enterprise Valuation
Apogee Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 19.38, with a Debt / Equity ratio of 0.
| Current Ratio | 19.38 |
| Quick Ratio | 19.38 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.29 |
| Cash Flow / Debt | -67.9 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.22% and return on capital (ROIC) is -24.35%.
| Return on Equity (ROE) | -0.22% |
| Return on Assets (ROA) | -0.21% |
| Return on Capital (ROIC) | -24.35% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -922.91K |
| Employee Count | 91 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 93.83% in the last 52 weeks. The beta is 2.32, so Apogee Therapeutics 's price volatility has been higher than the market average.
| Beta | 2.32 |
| 52-Week Price Change | 93.83% |
| 50-Day Moving Average | 51.87 |
| 200-Day Moving Average | 50.71 |
| Relative Strength Index (RSI) | 40.62 |
| Average Volume (20 Days) | 469.92K |
Income Statement
In the last 12 months, Apogee Therapeutics had revenue of $0 and earned -$83.98M in profits. Earnings per share was $-3.36.
| Revenue | 0 |
| Gross Profit | 0 |
| Operating Income | -93.00M |
| Net Income | -83.98M |
| EBITDA | -83.98M |
| EBIT | - |
| Earnings Per Share (EPS) | -3.36 |
Balance Sheet
The company has $118.32M in cash and $2.03M in debt, giving a net cash position of $116.28M.
| Cash & Cash Equivalents | 118.32M |
| Total Debt | 2.03M |
| Net Cash | 116.28M |
| Retained Earnings | -123.77M |
| Total Assets | 776.29M |
| Working Capital | 501.87M |
Cash Flow
In the last 12 months, operating cash flow was -$74.76M and capital expenditures -$167.00K, giving a free cash flow of -$74.93M.
| Operating Cash Flow | -74.76M |
| Capital Expenditures | -167.00K |
| Free Cash Flow | -74.93M |
| FCF Per Share | -3 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
APGE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -7.59% |
| FCF Yield | -2.89% |
Analyst Forecast
The average price target for APGE is $89, which is 101% higher than the current price. The consensus rating is "Buy".
| Price Target | $89 |
| Price Target Difference | 101% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | 36.6 |
| Piotroski F-Score | 1 |